版本:
中国

BRIEF-Calithera says FDA fast track designation granted to CB-839

June 7 Calithera Biosciences Inc:

* Calithera Biosciences announces FDA fast track designation granted to CB-839 for treatment of patients with renal cell carcinoma

* Calithera Biosciences - "look forward to initiating a global randomized trial of CB-839 in combination with everolimus for treatment of renal cell carcinoma in second half of 2017" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐